酪氨酸激酶抑制劑伊馬替尼對(duì)于斷裂點(diǎn)集中區(qū)/艾貝爾森（Bcr-Abl）陽(yáng)性白血病有著顯著的治療效果，但由于抗藥性的原因影響了其在臨床上的應(yīng)用。作為第二代Bcr-Abl酪氨酸激酶抑制劑巴氟替尼在一系列臨床前和臨床后研究中表現(xiàn)出了良好的應(yīng)用前景。

Although the tyrosine kinase inhibitor imatinib has the obvious efficacy on breakpoint cluster region-Abelson (Bcr-Abl) leukemia. However, clinical application is limited due to its drug-resistance. As the second generation Bcr-Abl tyrosine kinase inhibitor, bafetinb has a bright prospect in before and after clinical research.